The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration
- 1 January 2012
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 108 (08) , 357-366
Abstract
Angiogenesis, the sprouting of blood vessels form pre-existing vasculature after injury or in neoplastic diseases, is initiated by growth factor-induced endothelial cell migration. Recently, the major angiogenic growth factor VEGF165 has become the target of therapeutic interventions. However, this approach has been clinically proven to be of limited efficacy, which might be due to the fact that tumour angiogenesis is not only induced by VEGF, but also by a variety of other growth factors. Thus, the identification of a common downstream mediator of growth-factor-induced endothelial cell migration is mandatory to effectively interfere with (tumour-) angiogenesis. We found that the urokinase-type plas-minogen activator (uPA)-system, which affects proteolytic as well as adhesive capacities, represents an essential regulatory mechanism in growth factor-induced endothelial cell migration and invasion. This mechanism was not limited to VEGF165, but mediated pro-angiogenic endothelial cell behaviour induced by various growth factors. Thus, VEGF165, VEGF-E, FGF-2, EGF as well as HGF induced a PI3k-dependent activation of pro-uPA when bound to uPAR, which led to an increase in cell surface fibrinolytic activity. As a consequence, uPAR became internalised and redistributed via LDLR-proteins. Interference with these events led to a reduced migratory response of endothelial cells towards VEGF in vitro as well as endothelial cell invasion in vivo. These data give first evidence that the uPA-system, which represents the only level-of-evidence-1 cancer biomarker system for prognosis and/or prediction in node negative breast cancer, might directly affect (tumour-) angiogenesis.Keywords
This publication has 41 references indexed in Scilit:
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE StudyOphthalmology, 2011
- Molecular Predictors of Response to Antiangiogenesis TherapiesThe Cancer Journal, 2011
- Regulation of cell signalling by uPARNature Reviews Molecular Cell Biology, 2010
- FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nature Reviews Cancer, 2008
- Vascular Endothelial Growth Factor: Basic Science and Clinical ProgressEndocrine Reviews, 2004
- Vascular Endothelial Growth Factor Receptor-2–Induced Initial Endothelial Cell Migration Depends on the Presence of the Urokinase ReceptorCirculation Research, 2004
- Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cellsBlood, 2004
- Urokinase-type Plasminogen Activator Receptor (CD87) Is a Ligand for Integrins and Mediates Cell-Cell InteractionJournal of Biological Chemistry, 2001
- Mechanisms of angiogenesis and arteriogenesisNature Medicine, 2000
- Recycling of the urokinase receptor upon internalization of the uPA:serpin complexesThe EMBO Journal, 1997